The prestigious international journal Journal of Alzheimer's Disease has recently published a study entitled "Clinical-Based Validation of Brain Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia" in which the accuracy of beta-amyloid proteins has been measured, tau and phospho-tau to the cerebrospinal fluid the diagnosis of Alzheimer's in people with mild cognitive impairment or with dementia.
News
The Journal of Alzheimer 's Disease publishes an article by the Neurology Service and the Center for Diagnostic Technology (CTD)
The authors of the article are several professionals of the Neurology service of the MútuaTerrassa University Hospital as well as the Diagnostic Technology Center (CTD). There is also the area of immunology of Catlab as well as the University Hospital Vall d'Hebron, and even American researchers.
In the study, the levels of the mentioned proteins have been validated with the results of cerebral amyloid PET with florbetapir, which visualizes the amyloid fiber deposits in the cerebral cortex in Alzheimer's patients.
Researchers have been able to determine cut-points that improve diagnostic accuracy. The most sensitive and specific marker for the diagnosis of Alzheimer's disease was the quotient of the tau / beta-amyloid proteins (sensitivity of 92% and specificity of 84%).
These results are a step forward for clinical management, diagnosis and prognosis, and to improve the quality of the information provided to patients and their families.